Biology and Treatment of Acute Lymphoblastic Leukemia

Hematology/Oncology Clinics of North America

Volumn 24, Issue 1, 2010, Pages 1-18

  Pieters, Rob ^a   Carroll, William L ^b  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acute lymphoblastic leukemia; Adolescents; Chemotherapy; Children; Genomics; Targeted therapy

Indexed keywords

ANTHRACYCLINE; ASPARAGINASE; BCR ABL PROTEIN; CYTARABINE; DEXAMETHASONE; GAMMA SECRETASE INHIBITOR; GLUCOCORTICOID; HYBRID PROTEIN; MERCAPTOPURINE; METHOTREXATE; MIXED LINEAGE LEUKEMIA PROTEIN; NELARABINE; PREDNISONE; TIOGUANINE; TRANSCRIPTION FACTOR ETV6 TRANSCRIPTION FACTOR RUNX1 FUSION PROTEIN; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AGE; ALLOGENEIC STEM CELL TRANSPLANTATION; AVASCULAR NECROSIS; BEHAVIOR DISORDER; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER RADIOTHERAPY; CHILD HEALTH CARE; CLINICAL TRIAL; CONSTIPATION; CUSHINGOID SYNDROME; DIABETES MELLITUS; DIPLOIDY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG SUBSTITUTION; DRUG TARGETING; DRUG WITHDRAWAL; EVENING DOSAGE; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION PROFILING; GENE FUSION; GENE MUTATION; GENETIC ASSOCIATION; GENOME ANALYSIS; HUMAN; HYPERDIPLOIDY; HYPERGLYCEMIA; IMMUNOPHENOTYPING; LEUKEMIA RELAPSE; MAINTENANCE THERAPY; MORNING DOSAGE; MUCOSA INFLAMMATION; NEUROPATHY; NONHUMAN; OSTEOPOROSIS; PANCREATITIS; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; T CELL LEUKEMIA; THROMBOEMBOLISM; THROMBOSIS; TREATMENT RESPONSE;

CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 74849104314     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2009.11.014     Document Type: Review

References (103)

1. Greaves M. Infection, immune responses and the aetiology of childhood leukaemia. Nat Rev Cancer 6 3 (2006) 193-203
2. Fischer S., Mann G., Konrad M., et al. Screening for leukemia- and clone-specific markers at birth in children with T cell precursor ALL suggests a predominantly postnatal origin. Blood 110 (2007) 3036-3038
3. Conter V., Arico M., Valsecchi M.G., et al. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) acute lymphoblastic leukemia studies, 1982-1995. Leukemia 14 12 (2000) 2196-2204
4. Schrappe M., Reiter A., Zimmerman M., et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia 14 12 (2000) 2205-2222
5. Gaynon P.S., Trigg M.E., Heerema N.A., et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia 14 12 (2000) 2223-2233
6. Harms D.O., and Janka-Schaub G.E. Co-operative Study Group for Childhood Acute Lymphoblastic Leukemia (COALL): long-term follow-up of trials 82, 85, 89 and 92. Leukemia 14 12 (2000) 2234-2239
7. Kamps W.A., Veerman A.J., van Wering E.R., et al. Long-term follow-up of Dutch Childhood Leukemia Study Group (DCLSG) protocols for children with acute lymphoblastic leukemia, 1984-1991. Leukemia 14 12 (2000) 2240-2246
8. Silverman L.B., Declerck L., Gelber R.D., et al. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995). Leukemia 14 12 (2000) 2247-2256
9. Vilmer E., Suciu S., Ferster A., et al. Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Children Leukemia Cooperative Group. Leukemia 14 12 (2000) 2257-2266
10. Gustafsson G., Schmiegelow K., Forestier E., et al. Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO). Leukemia 14 12 (2000) 2267-2275
11. Pui C.H., Boyett J.M., Rivera G.K., et al. Long-term results of total therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia 14 12 (2000) 2286-2294
12. Aricò M., Valsecchi M.G., Camitta B., et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 342 14 (2000) 998-1006
13. Szczepański T., Orfo A., van der Velden V.H., et al. Minimal residual disease in leukaemia patients. Lancet Oncol 2 7 (2001) 409-417
14. Pieters R., den Boer M.L., Durian M., et al. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia-implications for treatment of infants. Leukemia 12 9 (1998) 1344-1348
15. Ramakers-van Woerden N.L., Pieters R., Hoelzer D., et al. In vitro drug resistance profile of Philadelphia positive acute lymphoblastic leukemia is heterogeneous and related to age: a report of the Dutch and German Leukemia Study Groups. Med Pediatr Oncol 38 6 (2002) 379-386
16. Biondi A., Cimino G., Pieters R., et al. Biological and therapeutic aspects of infant leukemia. Blood 96 1 (2000) 24-33
17. Pieters R., Schrappe M., De Lorenzo P., et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet 370 9583 (2007) 240-250
18. Hilden J.M., Dinndorf P.A., Meerbaum S.O., et al. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group. Blood 108 2 (2006) 441-451
19. Rots M.G., Pieters R., Peters G.J., et al. Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia. Blood 93 5 (1999) 1677-1683
20. Heerema N.A., Sather H.N., Sensel M.G., et al. Prognostic impact of trisomies of chromosomes 10, 17, and 5 among children with acute lymphoblastic leukemia and high hyperdiploidy (>50 chromosomes). J Clin Oncol 18 9 (2000) 1876-1887
21. Kaspers G.J., Smets L.A., Pieters R., et al. Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: results of an in vitro study. Blood 85 3 (1995) 751-756
22. Ramakers-van Woerden N.L., Pieters R., Loonen A.H., et al. TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. Blood 96 3 (2000) 1094-1099
23. Stams W.A., den Boer M.L., Holleman A., et al. Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia. Blood 105 11 (2005) 4223-4225
24. Stams W.A., den Boer M.L., Beverloo H.B., et al. Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)+ pediatric ALL. Blood 101 7 (2003) 2743-2747
25. Frost B.M., Froestier E., Gustafsson G., et al. Translocation t(12;21) is related to in vitro cellular drug sensitivity to doxorubicin and etoposide in childhood acute lymphoblastic leukemia. Blood 104 8 (2004) 2452-2457
26. Pui C.H., Gaynon P.S., Boyett J.M., et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 359 9321 (2002) 1909-1915
27. Jansen M.W., Corral L., van der Velden V.H., et al. Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement. Leukemia 21 4 (2007) 633-641
28. Armstrong S.A., Staunton J.E., Silverman L.B., et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 30 1 (2002) 41-47
29. Dordelmann M., Reiter A., Borkhardt A., et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood 94 4 (1999) 1209-1217
30. Ramakers-van Woerden N.L., Beverloo H.B., Veerman A.J., et al. In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype. Leukemia 18 3 (2004) 521-529
31. Stam R.W., den Boer M.L., Meijerink J.P., et al. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood 101 4 (2003) 1270-1276
32. Ramakers-van Woerden N.L., Pieters R., Rots M.G., et al. Infants with acute lymphoblastic leukemia: no evidence for high methotrexate resistance. Leukemia 16 5 (2002) 949-951
33. Stam R.W., van den Heuvel-Eibrink M.M., den Boer M.L., et al. Multidrug resistance genes in infant acute lymphoblastic leukemia: Ara-C is not a substrate for the breast cancer resistance protein. Leukemia 18 1 (2004) 78-83
34. Thompson P.A., Murry D.J., Rosner G.L., et al. Methotrexate pharmacokinetics in infants with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 59 6 (2007) 847-853
35. Schrappe M., Arico M., Harbott J., et al. Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome. Blood 92 8 (1998) 2730-2741
36. Graux C., Cools J., Michaux L., et al. Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast. Leukemia 20 9 (2006) 1496-1510
37. Breit S., Stanulla M., Flohr T., et al. Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood 108 4 (2006) 1151-1157
38. Moorman A.V., Richards S.M., Robinson H.M., et al. Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21). Blood 109 6 (2007) 2327-2330
39. Nachman J.B., Heerema N.A., Sather H., et al. Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood 110 4 (2007) 1112-1115
40. Bassal M., La M.K., Whitlock J.A., et al. Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG-1952. Pediatr Blood Cancer 44 1 (2005) 21-28
41. Whitlock J.A., Sather H.N., Gaynon P., et al. Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 106 13 (2005) 4043-4049
42. Tubergen D.G., Gilchrist G.S., O'Brien R.T., et al. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial. J Clin Oncol 11 (1993) 527-537
43. Bostrom B.C., Sensel M.R., Sather H.N., et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 101 10 (2003) 3809-3817
44. Mitchell C.D., Richards S.M., Kinsey S.E., et al. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol 129 6 (2005) 734-745
45. Igarashi S., Manabe A., Ohara A., et al. No advantage of dexamethasone over prednisolone for the outcome of standard- and intermediate-risk childhood acute lymphoblastic leukemia in the Tokyo Children's Cancer Study Group L95-14 protocol. J Clin Oncol 23 27 (2005) 6489-6498
46. Kaspers G.J., Veerman A.J., Popp-Snijders C., et al. Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. Med Pediatr Oncol 27 2 (1996) 114-121
47. Ito C., Evans W.E., McNinch L., et al. Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. J Clin Oncol 14 8 (1996) 2370-2376
48. Duval M., Suciu S., Ferster A., et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood 99 8 (2002) 2734-2739
49. Moghrabi A., Levy D.E., Asselin B., et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 109 3 (2007) 896-904
50. Appel I.M., Pinheiro J.P., den Boer M.L., et al. Lack of asparagine depletion in the cerebrospinal fluid after one intravenous dose of PEG-asparaginase: a window study at initial diagnosis of childhood ALL. Leukemia 17 11 (2003) 2254-2256
51. Pession A., Valsecchi M.G., Masera G., et al. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. J Clin Oncol 23 28 (2005) 7161-7167
52. Rizzari C., Vasecchi M.G., Arico M., et al. Effect of protracted high-dose L-asparaginase given as a second exposure in a Berlin-Frankfurt-Munster-based treatment: results of the randomized 9102 intermediate-risk childhood acute lymphoblastic leukemia study-a report from the Associazione Italiana Ematologia Oncologia Pediatrica. J Clin Oncol 19 5 (2001) 1297-1303
53. Amylon M.D., Shuster J., Pullen J., et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia 13 3 (1999) 335-342
54. Avramis V.I., Sencer C., Periclou A.P., et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 99 6 (2002) 1986-1994
55. Silverman L.B., Gelber R.D., Dalton V.K., et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 97 5 (2001) 1211-1218
56. Clarke M., Gaynon P., Hann I., et al. CNS-directed therapy for childhood acute lymphoblastic leukemia: childhood ALL Collaborative Group overview of 43 randomized trials. J Clin Oncol 21 9 (2003) 1798-1809
57. Matloub Y., Lindemulder S., Gaynon P.S., et al. Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group. Blood 108 4 (2006) 1165-1173
58. Harms D.O., Gobel U., Spaar H.J., et al. Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: results of the randomized trial COALL-92. Blood 102 8 (2003) 2736-2740
59. Vora A., Mitchell C.D., Lennard L., et al. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial. Lancet 368 9544 (2006) 1339-1348
60. Relling M.V., Hancock M.L., Boyett J.M., et al. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood 93 9 (1999) 2817-2823
61. Lilleyman J.S., and Lennard L. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia. Lancet 343 8907 (1994) 1188-1190
62. McLeod H.L., Relling M.V., Liu Q., et al. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood 85 7 (1995) 1897-1902
63. Aricó M., Baruchel A., Bertrand Y., et al. The seventh international childhood acute lymphoblastic leukemia workshop report: palermo, Italy, January 29-30, 2005. Leukemia 19 7 (2005) 1145-1152
64. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12,000 randomised children. Childhood ALL Collaborative Group. Lancet 347 9018 (1996) 1783-1788
65. Lange B.J., Bostrom B.C., Cherlow J.M., et al. Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 99 3 (2002) 825-833
66. Nachman J.B., Sather H.N., Sensel M.G., et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 338 23 (1998) 1663-1671
67. Kamps W.A., Bokkerink J.P., Hahlen K., et al. Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM-6 without cranial radiotherapy: results of Dutch Childhood Leukemia Study Group Protocol ALL-7 (1988-1991). Blood 94 4 (1999) 1226-1236
68. Toyoda Y., Manabe A., Tsuchida M., et al. Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood. J Clin Oncol 18 7 (2000) 1508-1516
69. Conter V., Valsecchi M.G., Silvestri D., et al. Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial. Lancet 369 9556 (2007) 123-131
70. Veerman A.J., Hahlen K., Kamps W.A., et al. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. J Clin Oncol 14 3 (1996) 911-918
71. Balduzzi A., Valsecchi M.G., Uderzo C., et al. Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study. Lancet 366 9486 (2005) 635-642
72. Ribera J.M., Ortega J.J., Oriol A., et al. Comparison of intensive chemotherapy, allogeneic, or autologous stem-cell transplantation as postremission treatment for children with very high risk acute lymphoblastic leukemia: PETHEMA ALL-93 Trial. J Clin Oncol 25 1 (2007) 16-24
73. Schrauder A., Reiter A., Gadner H., et al. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95. J Clin Oncol 24 36 (2006) 5742-5749
74. Boissel N., Auclerc M.F., Lheritier V., et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 21 5 (2003) 774-780
75. de Bont J.M., Holt B., Dekker A.W., et al. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia 18 12 (2004) 2032-2035
76. Deangelo D.J. The treatment of adolescents and young adults with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program (2005) 123-130
77. Ramanujachar R., Richards S., Hann I., et al. Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials. Pediatr Blood Cancer 48 3 (2007) 254-261
78. Christensen M.S., Heyman M., Mottonen M., et al. Treatment-related death in childhood acute lymphoblastic leukaemia in the Nordic countries: 1992-2001. Br J Haematol 131 1 (2005) 50-58
79. Caruso V., Iacoviello L., Di Castelnuovo A., et al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood 108 7 (2006) 2216-2222
80. Carroll W.L., Bhojwani D., Min D.J., et al. Childhood acute lymphoblastic leukemia in the age of genomics. Pediatr Blood Cancer 46 5 (2006) 570-578
81. Yeoh E.J., Ross M.E., Shurtleff S.A., et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1 2 (2002) 133-143
82. Ross M.E., Zhou X., Song G., et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood 102 8 (2003) 2951-2959
83. Holleman A., Cheok M.H., den Boer M.L., et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 351 6 (2004) 533-542
84. Lugthart S., Cheok M.H., den Boer M.L., et al. Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. Cancer Cell 7 4 (2005) 375-386
85. Wei G., Twomey D., Lamb J., et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 10 4 (2006) 331-342
86. Bhojwani D., Kang H., Moskowitz N.P., et al. Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. Blood 108 2 (2006) 711-717
87. Armstrong S.A., Kung A.L., Mabon M.E., et al. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 3 2 (2003) 173-183
88. Stam R.W., den Boer M.L., Schneider P., et al. Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. Blood 106 7 (2005) 2484-2490
89. Stam R.W., Schneider P., de Lorenzo P., et al. Prognostic significance of high-level FLT3 expression in MLL-rearranged infant acute lymphoblastic leukemia. Blood 110 7 (2007) 2774-2775
90. Mullighan C.G., Goorha S., Radtke I., et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446 7137 (2007) 758-764
91. Lahortiga I., De Keersmaecker K., Van Vlierberghe P., et al. Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nat Genet 39 5 (2007) 593-595
92. van Vlierberghe P., Meijerink J.P., Lee C., et al. A new recurrent 9q34 duplication in pediatric T-cell acute lymphoblastic leukemia. Leukemia 20 7 (2006) 1245-1253
93. Van Vlierberghe P., van Grotel M., Beverloo H.B., et al. The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia. Blood 108 10 (2006) 3520-3529
94. Cheok M.H., and Evans W.E. Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat Rev Cancer 6 2 (2006) 117-129
95. Lu J., Getz G., Miska E.A., et al. MicroRNA expression profiles classify human cancers. Nature 435 7043 (2005) 834-838
96. Champagne M.A., Capdeville R., Krailo M., et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. Blood 104 9 (2004) 2655-2660
97. Talpaz M., Shah N.P., Kantarjian H., et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354 24 (2006) 2531-2541
98. Kantarjian H., Giles F., Wunderle L., et al. Nilotinib in imatinib-resistan CML and Philadelphia chromosome-positive ALL. N Engl J Med 354 24 (2006) 2542-2551
99. Gandhi V., Kilpatrick J.M., Plunkett W., et al. A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine). Blood 106 13 (2005) 4253-4260
100. Kurtzberg J., Ernst T.J., Keating M.J., et al. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol 23 15 (2005) 3396-3403
101. Berg S.L., Blaney S.M., Devidas M., et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol 23 15 (2005) 3376-3382
102. Stam R.W., den Boer M.L., Passier M.M., et al. Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemia. Leukemia 20 2 (2006) 264-271
103. Kishi S., Cheng C., French D., et al. Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood 109 10 (2007) 4151-4157